2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma: A bicenter trial

Research output: Contribution to journalResearch articleContributedpeer-review


  • Inga Buchmann - , Ulm University (Author)
  • Michael Reinhardt - , University of Freiburg (Author)
  • Klaus Elsner - , Ulm University (Author)
  • Donald Bunjes - , Ulm University (Author)
  • Carsten Altehoefer - , University of Freiburg (Author)
  • Jürgen Finke - , University of Freiburg (Author)
  • Ernst Moser - , University of Freiburg (Author)
  • Gerhard Glatting - , Ulm University (Author)
  • Jörg Kotzerke - , Ulm University (Author)
  • Carl A. Guhlmann - , Ulm University (Author)
  • Holger Schirrmeister - , Ulm University (Author)
  • Sven N. Reske - , Ulm University (Author)


BACKGROUND. The authors undertook a prospective evaluation of the clinical value of 2-fluoro [18-1-2·deoxyglucose positron emission tomography (FDG-PET) in the detection and staging of malignant lymphoma compared with computed tomography (CT) and bone marrow biopsy (BMB). METHODS. Fifty-two consecutive patients with untreated malignant lymphoma were evaluated prospectively in a bicenter study. FDG-PET, CT, and BMB were performed for investigating lymph node/extranodal manifestations and bone marrow infiltration. Thirty-three percnt of the discrepant results were verified by biopsy, magnetic resonance imaging, or clinical follow-up (range, 4-24 month). RESULTS. Altogether, 1297 anatomic regions (lymph nodes, organs, and bone marrow) were evaluated. FDG-PET and CT scans were compared by receiver operating characteristic (ROC) curve analysis. The area under the BOC curve were as follows: lymph nodes, 0.996 (PET) and 0.916 (CT); extranodal, 0.999 (PET) and 0.916 (CT); supradiaphragmatic, 0.996 (PET) and 0.905 (CT); and infradiaphragmatic, 0.999 (PET) and 0.952 (CT). In these analyses, FDG·PET was significantly superior to CT (P < 0.05), except in infradiaphragmatic regions, in which the two methods produced equivalent results. In detecting bone marrow infiltration, FDG-PET was superior to CT and was equivalent to BMB. In 4 of 52 patients (8%), FDG-PET led to an upstaging and a change of therapy. CONCLUSIONS. Noninvasive FDG-PET is very accurate in the staging of malignant lymphoma. Compared with standard staging modalities (CT and BMB), PET was significantly superior and led to changes in the therapy regimen for 8% of patients. 889-99


Original languageEnglish
Pages (from-to)889-899
Number of pages11
Issue number5
Publication statusPublished - 1 Mar 2001
Externally publishedYes

External IDs

PubMed 11251940


Sustainable Development Goals

ASJC Scopus subject areas


  • 2-(fluorine-18)fluoro-2-deoxy-D-glucose, Detection, Initial staging, Lymphoma, M. Hodgkin, Non-Hodgkin lymphoma, Positron emission tomography, Upstaging.